MX350024B - Formas polimorfas del ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2- benzisoxazol-3-il]oxi}metil)piperidin-1-il]metil}-tetrahidro-2h-p iran-4-carboxílico. - Google Patents
Formas polimorfas del ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2- benzisoxazol-3-il]oxi}metil)piperidin-1-il]metil}-tetrahidro-2h-p iran-4-carboxílico.Info
- Publication number
- MX350024B MX350024B MX2013013355A MX2013013355A MX350024B MX 350024 B MX350024 B MX 350024B MX 2013013355 A MX2013013355 A MX 2013013355A MX 2013013355 A MX2013013355 A MX 2013013355A MX 350024 B MX350024 B MX 350024B
- Authority
- MX
- Mexico
- Prior art keywords
- methyl
- trifluoroethoxy
- pyran
- piperidin
- tetrahydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011111901 | 2011-05-18 | ||
| PCT/JP2012/003288 WO2012157288A1 (en) | 2011-05-18 | 2012-05-18 | Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013013355A MX2013013355A (es) | 2014-01-08 |
| MX350024B true MX350024B (es) | 2017-08-23 |
Family
ID=47176633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013013355A MX350024B (es) | 2011-05-18 | 2012-05-18 | Formas polimorfas del ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2- benzisoxazol-3-il]oxi}metil)piperidin-1-il]metil}-tetrahidro-2h-p iran-4-carboxílico. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9187463B2 (ja) |
| EP (1) | EP2710002B1 (ja) |
| JP (1) | JP5608873B2 (ja) |
| KR (3) | KR102459766B1 (ja) |
| CN (1) | CN103702995B (ja) |
| BR (1) | BR112013029319A2 (ja) |
| CA (1) | CA2836372C (ja) |
| ES (1) | ES2618494T3 (ja) |
| HK (2) | HK1195066A1 (ja) |
| MX (1) | MX350024B (ja) |
| RU (1) | RU2616978C2 (ja) |
| TW (1) | TWI537265B (ja) |
| WO (1) | WO2012157288A1 (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2637539T3 (es) * | 2012-11-21 | 2017-10-13 | Raqualia Pharma Inc | Polimorfos de ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2-benzoisoxazol-3-il]oxi}metil)piperidin-1-il]metil}-tetrahidro-2H-piran-4-carboxílico como agonistas del receptor de 5-hidroxitriptamina-4 (5-HT4) para el tratamiento de enfermedades gastrointestinales |
| PT3113774T (pt) | 2014-03-06 | 2022-02-28 | Elanco Animal Health Incorporated | Composições de grapiprant e métodos de utilização das mesmas |
| ES2919346T3 (es) | 2014-03-06 | 2022-07-26 | Elanco Animal Health Incorporated | Forma cristalina x2 de grapiprant |
| MX366985B (es) * | 2014-05-20 | 2019-08-01 | Raqualia Pharma Inc | Sales derivadas de bencisoxazol. |
| US12109218B2 (en) | 2014-12-09 | 2024-10-08 | Aratana Therapeutics, Inc. | Compositions of grapiprant and methods for using the same |
| KR20230022038A (ko) | 2021-08-06 | 2023-02-14 | 주식회사 엘지에너지솔루션 | 건식 전극 필름 제조 방법 및 상기 전극 필름 제조 시스템 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| ES2144355B1 (es) * | 1997-12-30 | 2001-01-01 | Ferrer Int | Compuestos derivados del cromeno. |
| CA2598516C (en) | 2005-02-25 | 2010-05-11 | Pfizer Inc. | Benzisoxazole derivatives |
| CA2788656A1 (en) * | 2010-02-16 | 2011-08-25 | Pfizer Inc. | (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors |
| CN108159048A (zh) * | 2011-03-23 | 2018-06-15 | 拉夸里亚创药株式会社 | 作为促动力药的5-ht4受体激动剂 |
-
2012
- 2012-05-18 MX MX2013013355A patent/MX350024B/es active IP Right Grant
- 2012-05-18 RU RU2013156069A patent/RU2616978C2/ru active
- 2012-05-18 ES ES12786698.6T patent/ES2618494T3/es active Active
- 2012-05-18 WO PCT/JP2012/003288 patent/WO2012157288A1/en active Application Filing
- 2012-05-18 KR KR1020217025664A patent/KR102459766B1/ko active IP Right Grant
- 2012-05-18 BR BR112013029319A patent/BR112013029319A2/pt not_active IP Right Cessation
- 2012-05-18 CN CN201280023928.0A patent/CN103702995B/zh active Active
- 2012-05-18 JP JP2013552437A patent/JP5608873B2/ja active Active
- 2012-05-18 EP EP12786698.6A patent/EP2710002B1/en active Active
- 2012-05-18 KR KR1020197003303A patent/KR20190015614A/ko active IP Right Grant
- 2012-05-18 US US14/118,377 patent/US9187463B2/en active Active
- 2012-05-18 TW TW101117945A patent/TWI537265B/zh active
- 2012-05-18 CA CA2836372A patent/CA2836372C/en active Active
- 2012-05-18 KR KR1020137032263A patent/KR20140041524A/ko active Application Filing
-
2014
- 2014-08-19 HK HK14108477.9A patent/HK1195066A1/zh unknown
- 2014-09-04 HK HK14109019.2A patent/HK1195559A1/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR102459766B1 (ko) | 2022-10-26 |
| US9187463B2 (en) | 2015-11-17 |
| BR112013029319A2 (pt) | 2017-01-31 |
| US20140187583A1 (en) | 2014-07-03 |
| TW201300382A (zh) | 2013-01-01 |
| RU2013156069A (ru) | 2015-06-27 |
| EP2710002A1 (en) | 2014-03-26 |
| HK1195559A1 (zh) | 2014-11-14 |
| KR20140041524A (ko) | 2014-04-04 |
| CA2836372C (en) | 2020-09-22 |
| MX2013013355A (es) | 2014-01-08 |
| HK1195066A1 (zh) | 2014-10-31 |
| EP2710002A4 (en) | 2014-10-01 |
| JP5608873B2 (ja) | 2014-10-15 |
| RU2616978C2 (ru) | 2017-04-19 |
| EP2710002B1 (en) | 2017-03-01 |
| KR20210104170A (ko) | 2021-08-24 |
| ES2618494T3 (es) | 2017-06-21 |
| KR20190015614A (ko) | 2019-02-13 |
| CN103702995B (zh) | 2016-04-13 |
| WO2012157288A1 (en) | 2012-11-22 |
| TWI537265B (zh) | 2016-06-11 |
| CN103702995A (zh) | 2014-04-02 |
| CA2836372A1 (en) | 2012-11-22 |
| JP2014513665A (ja) | 2014-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011110876A8 (en) | Novel salts for the manufacture of pharmaceutical compositions | |
| MX361020B (es) | Procesos para preparar compuestos heterociclicos, incluida trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo [3,2,1]octano-2-carboxam ida y sales de la misma. | |
| TW201129555A (en) | Process for the manufacture of dabigatrane etexilate | |
| MD20140002A2 (ro) | Indazoli | |
| IN2014MN02459A (ja) | ||
| MX2011008864A (es) | Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales. | |
| SG195319A1 (en) | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | |
| MX350024B (es) | Formas polimorfas del ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2- benzisoxazol-3-il]oxi}metil)piperidin-1-il]metil}-tetrahidro-2h-p iran-4-carboxílico. | |
| MX2010012390A (es) | Derivados de indazoles sustituidos con fenilo o piridinilo. | |
| GEP20217235B (en) | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | |
| MX347841B (es) | Procedimiento para preparar derivados de antranilamida sustituidos con tetrazoles y polimorfos cristalinos novedosos de estos derivados. | |
| MX2013012652A (es) | Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12. | |
| WO2013067349A9 (en) | Novel chemistry used in biosensors | |
| ME00680B (me) | Nova jedinjenja diozmetina, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže | |
| WO2014188453A3 (en) | Novel process for the preparation of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl) phenyl]-2-methylpropanoic acid | |
| PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
| MX350862B (es) | Acidos de piperidinil naftilacetico. | |
| PL401473A1 (pl) | Nowe, silnie fluorescencyjne substancje heterocykliczne i sposób ich otrzymywania | |
| IN2014DN06122A (ja) | ||
| UA109460C2 (uk) | N-гетарилметилпіразолілкарбоксаміди | |
| MX353994B (es) | Formas polimorfas. | |
| MX2013010006A (es) | Derivados de sec-hidroxiciclohexilo como inhibidores de lipasa sensible a hormonas (hsl) para el tratamiento de diabetes. | |
| MY160625A (en) | Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation | |
| UA110822C2 (uk) | Піперидинілмонокарбонові кислоти як агоністи s1p1-рецепторів | |
| MX366985B (es) | Sales derivadas de bencisoxazol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |